nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—brain cancer	0.47	0.679	CbGaD
Afatinib—EGFR—brain cancer	0.222	0.321	CbGaD
Afatinib—ABCG2—Carboplatin—brain cancer	0.0168	0.467	CbGbCtD
Afatinib—ABCG2—Etoposide—brain cancer	0.0141	0.392	CbGbCtD
Afatinib—Pulmonary toxicity—Lomustine—brain cancer	0.008	0.106	CcSEcCtD
Afatinib—ABCB1—Etoposide—brain cancer	0.00508	0.141	CbGbCtD
Afatinib—Pulmonary toxicity—Procarbazine—brain cancer	0.00508	0.0671	CcSEcCtD
Afatinib—Disease progression—Carmustine—brain cancer	0.0033	0.0437	CcSEcCtD
Afatinib—Pulmonary toxicity—Carmustine—brain cancer	0.00318	0.042	CcSEcCtD
Afatinib—PHKG2—hindbrain—brain cancer	0.00304	0.0489	CbGeAlD
Afatinib—DYRK1A—hindbrain—brain cancer	0.00263	0.0423	CbGeAlD
Afatinib—ERBB2—Podofilox—Etoposide—brain cancer	0.00239	1	CbGdCrCtD
Afatinib—PHKG2—brainstem—brain cancer	0.00174	0.028	CbGeAlD
Afatinib—HIPK4—gonad—brain cancer	0.00169	0.0272	CbGeAlD
Afatinib—Mucosal inflammation—Hydroxyurea—brain cancer	0.00161	0.0213	CcSEcCtD
Afatinib—ERBB4—brainstem—brain cancer	0.00157	0.0252	CbGeAlD
Afatinib—DYRK1A—brainstem—brain cancer	0.00151	0.0243	CbGeAlD
Afatinib—ERBB4—telencephalon—brain cancer	0.00139	0.0224	CbGeAlD
Afatinib—DYRK1A—telencephalon—brain cancer	0.00134	0.0215	CbGeAlD
Afatinib—EPHA6—gonad—brain cancer	0.00134	0.0215	CbGeAlD
Afatinib—PHKG2—gonad—brain cancer	0.00129	0.0208	CbGeAlD
Afatinib—HIPK4—endocrine gland—brain cancer	0.00128	0.0206	CbGeAlD
Afatinib—PHKG2—medulla oblongata—brain cancer	0.00122	0.0195	CbGeAlD
Afatinib—EGFR—telencephalon—brain cancer	0.00118	0.019	CbGeAlD
Afatinib—ERBB2—gonad—brain cancer	0.00116	0.0187	CbGeAlD
Afatinib—Vandetanib—VEGFA—brain cancer	0.00115	0.296	CrCbGaD
Afatinib—ABL1—hindbrain—brain cancer	0.00115	0.0184	CbGeAlD
Afatinib—ERBB4—pituitary gland—brain cancer	0.00113	0.0182	CbGeAlD
Afatinib—DYRK1A—gonad—brain cancer	0.00112	0.018	CbGeAlD
Afatinib—ERBB4—medulla oblongata—brain cancer	0.00109	0.0176	CbGeAlD
Afatinib—IRAK1—telencephalon—brain cancer	0.00104	0.0167	CbGeAlD
Afatinib—Interstitial lung disease—Carmustine—brain cancer	0.00102	0.0135	CcSEcCtD
Afatinib—EPHA6—endocrine gland—brain cancer	0.00101	0.0163	CbGeAlD
Afatinib—Mucosal inflammation—Etoposide—brain cancer	0.00101	0.0133	CcSEcCtD
Afatinib—EPHA6—head—brain cancer	0.000999	0.0161	CbGeAlD
Afatinib—ERBB4—midbrain—brain cancer	0.000999	0.0161	CbGeAlD
Afatinib—Renal failure—Lomustine—brain cancer	0.000999	0.0132	CcSEcCtD
Afatinib—Stomatitis—Lomustine—brain cancer	0.00099	0.0131	CcSEcCtD
Afatinib—Interstitial lung disease—Temozolomide—brain cancer	0.000985	0.013	CcSEcCtD
Afatinib—PHKG2—endocrine gland—brain cancer	0.000976	0.0157	CbGeAlD
Afatinib—ERBB4—spinal cord—brain cancer	0.000975	0.0157	CbGeAlD
Afatinib—Vandetanib—EGFR—brain cancer	0.00097	0.25	CrCbGaD
Afatinib—PHKG2—head—brain cancer	0.000964	0.0155	CbGeAlD
Afatinib—Gefitinib—EGFR—brain cancer	0.000922	0.237	CrCbGaD
Afatinib—HIPK4—brain—brain cancer	0.000916	0.0147	CbGeAlD
Afatinib—EPHA6—central nervous system—brain cancer	0.000912	0.0147	CbGeAlD
Afatinib—PHKG2—central nervous system—brain cancer	0.00088	0.0141	CbGeAlD
Afatinib—ERBB2—endocrine gland—brain cancer	0.000878	0.0141	CbGeAlD
Afatinib—ERBB4—endocrine gland—brain cancer	0.000878	0.0141	CbGeAlD
Afatinib—ERBB2—head—brain cancer	0.000867	0.0139	CbGeAlD
Afatinib—ERBB4—head—brain cancer	0.000867	0.0139	CbGeAlD
Afatinib—PHKG2—cerebellum—brain cancer	0.00086	0.0138	CbGeAlD
Afatinib—DYRK1A—endocrine gland—brain cancer	0.000845	0.0136	CbGeAlD
Afatinib—Gefitinib—CYP2C9—brain cancer	0.00084	0.216	CrCbGaD
Afatinib—DYRK1A—head—brain cancer	0.000834	0.0134	CbGeAlD
Afatinib—Alopecia—Lomustine—brain cancer	0.000806	0.0106	CcSEcCtD
Afatinib—ERBB2—central nervous system—brain cancer	0.000791	0.0127	CbGeAlD
Afatinib—ERBB4—central nervous system—brain cancer	0.000791	0.0127	CbGeAlD
Afatinib—Interstitial lung disease—Etoposide—brain cancer	0.000788	0.0104	CcSEcCtD
Afatinib—ERBB2—cerebellum—brain cancer	0.000773	0.0124	CbGeAlD
Afatinib—ERBB4—cerebellum—brain cancer	0.000773	0.0124	CbGeAlD
Afatinib—DYRK1A—central nervous system—brain cancer	0.000761	0.0122	CbGeAlD
Afatinib—IRAK1—midbrain—brain cancer	0.000748	0.012	CbGeAlD
Afatinib—DYRK1A—cerebellum—brain cancer	0.000744	0.012	CbGeAlD
Afatinib—Infection—Carboplatin—brain cancer	0.000736	0.00972	CcSEcCtD
Afatinib—EPHA6—brain—brain cancer	0.000724	0.0116	CbGeAlD
Afatinib—PHKG2—brain—brain cancer	0.000698	0.0112	CbGeAlD
Afatinib—ABL1—brainstem—brain cancer	0.000657	0.0106	CbGeAlD
Afatinib—EGFR—cerebellum—brain cancer	0.000655	0.0105	CbGeAlD
Afatinib—Pneumonia—Procarbazine—brain cancer	0.000649	0.00857	CcSEcCtD
Afatinib—Dry eye—Temozolomide—brain cancer	0.000644	0.00851	CcSEcCtD
Afatinib—Infection—Lomustine—brain cancer	0.000644	0.00851	CcSEcCtD
Afatinib—Stomatitis—Procarbazine—brain cancer	0.000629	0.00831	CcSEcCtD
Afatinib—ERBB2—brain—brain cancer	0.000628	0.0101	CbGeAlD
Afatinib—ERBB4—brain—brain cancer	0.000628	0.0101	CbGeAlD
Afatinib—Sepsis—Carmustine—brain cancer	0.000626	0.00827	CcSEcCtD
Afatinib—Epistaxis—Procarbazine—brain cancer	0.000608	0.00804	CcSEcCtD
Afatinib—DYRK1A—brain—brain cancer	0.000604	0.00971	CbGeAlD
Afatinib—Body temperature increased—Carboplatin—brain cancer	0.000586	0.00774	CcSEcCtD
Afatinib—ABL1—telencephalon—brain cancer	0.000583	0.00937	CbGeAlD
Afatinib—IRAK1—cerebellum—brain cancer	0.000578	0.00929	CbGeAlD
Afatinib—Decreased appetite—Lomustine—brain cancer	0.000563	0.00744	CcSEcCtD
Afatinib—EGFR—brain—brain cancer	0.000532	0.00855	CbGeAlD
Afatinib—Body temperature increased—Lomustine—brain cancer	0.000512	0.00677	CcSEcCtD
Afatinib—Alopecia—Procarbazine—brain cancer	0.000512	0.00676	CcSEcCtD
Afatinib—Mouth ulceration—Etoposide—brain cancer	0.000504	0.00666	CcSEcCtD
Afatinib—Infestation NOS—Hydroxyurea—brain cancer	0.000499	0.0066	CcSEcCtD
Afatinib—Infestation—Hydroxyurea—brain cancer	0.000499	0.0066	CcSEcCtD
Afatinib—ABL1—gonad—brain cancer	0.000487	0.00782	CbGeAlD
Afatinib—Stomatitis—Hydroxyurea—brain cancer	0.000487	0.00643	CcSEcCtD
Afatinib—Sepsis—Etoposide—brain cancer	0.000484	0.0064	CcSEcCtD
Afatinib—Hypokalaemia—Carmustine—brain cancer	0.000477	0.0063	CcSEcCtD
Afatinib—ABL1—pituitary gland—brain cancer	0.000475	0.00763	CbGeAlD
Afatinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000472	0.00624	CcSEcCtD
Afatinib—Dehydration—Temozolomide—brain cancer	0.000471	0.00622	CcSEcCtD
Afatinib—IRAK1—brain—brain cancer	0.00047	0.00755	CbGeAlD
Afatinib—Dry skin—Temozolomide—brain cancer	0.000464	0.00613	CcSEcCtD
Afatinib—Hypokalaemia—Temozolomide—brain cancer	0.000461	0.00609	CcSEcCtD
Afatinib—ABL1—medulla oblongata—brain cancer	0.000458	0.00736	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000456	0.00602	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000446	0.0059	CcSEcCtD
Afatinib—Cough—Procarbazine—brain cancer	0.00044	0.00581	CcSEcCtD
Afatinib—ABL1—midbrain—brain cancer	0.000419	0.00673	CbGeAlD
Afatinib—Vomiting—Lomustine—brain cancer	0.000412	0.00544	CcSEcCtD
Afatinib—Infection—Procarbazine—brain cancer	0.000409	0.0054	CcSEcCtD
Afatinib—ABL1—spinal cord—brain cancer	0.000409	0.00656	CbGeAlD
Afatinib—Upper respiratory tract infection—Temozolomide—brain cancer	0.000407	0.00537	CcSEcCtD
Afatinib—Pneumonia—Carmustine—brain cancer	0.000406	0.00536	CcSEcCtD
Afatinib—Renal failure—Carmustine—brain cancer	0.000397	0.00524	CcSEcCtD
Afatinib—Alopecia—Hydroxyurea—brain cancer	0.000396	0.00523	CcSEcCtD
Afatinib—Weight decreased—Temozolomide—brain cancer	0.000396	0.00523	CcSEcCtD
Afatinib—Stomatitis—Carmustine—brain cancer	0.000393	0.0052	CcSEcCtD
Afatinib—Urinary tract infection—Carmustine—brain cancer	0.000392	0.00518	CcSEcCtD
Afatinib—Pneumonia—Temozolomide—brain cancer	0.000392	0.00518	CcSEcCtD
Afatinib—Infestation—Temozolomide—brain cancer	0.00039	0.00515	CcSEcCtD
Afatinib—Infestation NOS—Temozolomide—brain cancer	0.00039	0.00515	CcSEcCtD
Afatinib—Nausea—Lomustine—brain cancer	0.000385	0.00509	CcSEcCtD
Afatinib—Stomatitis—Temozolomide—brain cancer	0.00038	0.00502	CcSEcCtD
Afatinib—Urinary tract infection—Temozolomide—brain cancer	0.000379	0.00501	CcSEcCtD
Afatinib—ABCB1—blood vessel—brain cancer	0.000374	0.00601	CbGeAlD
Afatinib—Insomnia—Procarbazine—brain cancer	0.000372	0.00492	CcSEcCtD
Afatinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000369	0.00487	CcSEcCtD
Afatinib—ABL1—endocrine gland—brain cancer	0.000368	0.00591	CbGeAlD
Afatinib—ABCG2—telencephalon—brain cancer	0.000368	0.00591	CbGeAlD
Afatinib—ABL1—head—brain cancer	0.000363	0.00583	CbGeAlD
Afatinib—Decreased appetite—Procarbazine—brain cancer	0.000358	0.00473	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000357	0.00472	CcSEcCtD
Afatinib—Connective tissue disorder—Carmustine—brain cancer	0.000356	0.0047	CcSEcCtD
Afatinib—Fatigue—Procarbazine—brain cancer	0.000355	0.00469	CcSEcCtD
Afatinib—Constipation—Procarbazine—brain cancer	0.000352	0.00465	CcSEcCtD
Afatinib—Urinary tract disorder—Temozolomide—brain cancer	0.000346	0.00457	CcSEcCtD
Afatinib—Connective tissue disorder—Temozolomide—brain cancer	0.000344	0.00455	CcSEcCtD
Afatinib—Urethral disorder—Temozolomide—brain cancer	0.000343	0.00453	CcSEcCtD
Afatinib—Eye disorder—Carmustine—brain cancer	0.000339	0.00447	CcSEcCtD
Afatinib—ABL1—central nervous system—brain cancer	0.000331	0.00532	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00033	0.00436	CcSEcCtD
Afatinib—Eye disorder—Temozolomide—brain cancer	0.000327	0.00432	CcSEcCtD
Afatinib—Body temperature increased—Procarbazine—brain cancer	0.000325	0.0043	CcSEcCtD
Afatinib—ABL1—cerebellum—brain cancer	0.000324	0.0052	CbGeAlD
Afatinib—Alopecia—Carmustine—brain cancer	0.00032	0.00423	CcSEcCtD
Afatinib—Mental disorder—Carmustine—brain cancer	0.000317	0.00419	CcSEcCtD
Afatinib—Infection—Hydroxyurea—brain cancer	0.000316	0.00418	CcSEcCtD
Afatinib—Mediastinal disorder—Temozolomide—brain cancer	0.000316	0.00417	CcSEcCtD
Afatinib—Malnutrition—Carmustine—brain cancer	0.000315	0.00417	CcSEcCtD
Afatinib—Pneumonia—Etoposide—brain cancer	0.000314	0.00415	CcSEcCtD
Afatinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000312	0.00413	CcSEcCtD
Afatinib—Infestation NOS—Etoposide—brain cancer	0.000312	0.00412	CcSEcCtD
Afatinib—Infestation—Etoposide—brain cancer	0.000312	0.00412	CcSEcCtD
Afatinib—Alopecia—Temozolomide—brain cancer	0.000309	0.00409	CcSEcCtD
Afatinib—Skin disorder—Hydroxyurea—brain cancer	0.000309	0.00409	CcSEcCtD
Afatinib—Renal failure—Etoposide—brain cancer	0.000307	0.00405	CcSEcCtD
Afatinib—Mental disorder—Temozolomide—brain cancer	0.000307	0.00405	CcSEcCtD
Afatinib—Back pain—Carmustine—brain cancer	0.000305	0.00403	CcSEcCtD
Afatinib—Malnutrition—Temozolomide—brain cancer	0.000305	0.00403	CcSEcCtD
Afatinib—Stomatitis—Etoposide—brain cancer	0.000304	0.00402	CcSEcCtD
Afatinib—ABCG2—pituitary gland—brain cancer	0.000299	0.00481	CbGeAlD
Afatinib—Dysgeusia—Temozolomide—brain cancer	0.000298	0.00394	CcSEcCtD
Afatinib—Asthenia—Procarbazine—brain cancer	0.000295	0.0039	CcSEcCtD
Afatinib—Hepatobiliary disease—Etoposide—brain cancer	0.000295	0.0039	CcSEcCtD
Afatinib—Back pain—Temozolomide—brain cancer	0.000295	0.0039	CcSEcCtD
Afatinib—Pruritus—Procarbazine—brain cancer	0.000291	0.00385	CcSEcCtD
Afatinib—ABCG2—medulla oblongata—brain cancer	0.000289	0.00464	CbGeAlD
Afatinib—Dyspnoea—Hydroxyurea—brain cancer	0.000284	0.00375	CcSEcCtD
Afatinib—Diarrhoea—Procarbazine—brain cancer	0.000281	0.00372	CcSEcCtD
Afatinib—Dyspepsia—Hydroxyurea—brain cancer	0.00028	0.0037	CcSEcCtD
Afatinib—Decreased appetite—Hydroxyurea—brain cancer	0.000277	0.00366	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—brain cancer	0.000277	0.00366	CcSEcCtD
Afatinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000275	0.00363	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—brain cancer	0.000275	0.00363	CcSEcCtD
Afatinib—Fatigue—Hydroxyurea—brain cancer	0.000275	0.00363	CcSEcCtD
Afatinib—Constipation—Hydroxyurea—brain cancer	0.000272	0.0036	CcSEcCtD
Afatinib—Dizziness—Procarbazine—brain cancer	0.000272	0.00359	CcSEcCtD
Afatinib—Cough—Temozolomide—brain cancer	0.000266	0.00351	CcSEcCtD
Afatinib—ABCG2—midbrain—brain cancer	0.000264	0.00424	CbGeAlD
Afatinib—ABL1—brain—brain cancer	0.000263	0.00423	CbGeAlD
Afatinib—Eye disorder—Etoposide—brain cancer	0.000262	0.00346	CcSEcCtD
Afatinib—Vomiting—Procarbazine—brain cancer	0.000262	0.00346	CcSEcCtD
Afatinib—Rash—Procarbazine—brain cancer	0.000259	0.00343	CcSEcCtD
Afatinib—Dermatitis—Procarbazine—brain cancer	0.000259	0.00342	CcSEcCtD
Afatinib—Headache—Procarbazine—brain cancer	0.000258	0.00341	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000258	0.0034	CcSEcCtD
Afatinib—ABCG2—spinal cord—brain cancer	0.000258	0.00414	CbGeAlD
Afatinib—Infection—Carmustine—brain cancer	0.000256	0.00338	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—brain cancer	0.000252	0.00334	CcSEcCtD
Afatinib—Body temperature increased—Hydroxyurea—brain cancer	0.000252	0.00333	CcSEcCtD
Afatinib—Alopecia—Etoposide—brain cancer	0.000248	0.00327	CcSEcCtD
Afatinib—Infection—Temozolomide—brain cancer	0.000247	0.00327	CcSEcCtD
Afatinib—Nausea—Procarbazine—brain cancer	0.000244	0.00323	CcSEcCtD
Afatinib—Nervous system disorder—Temozolomide—brain cancer	0.000244	0.00322	CcSEcCtD
Afatinib—Skin disorder—Temozolomide—brain cancer	0.000242	0.00319	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—brain cancer	0.000239	0.00316	CcSEcCtD
Afatinib—Back pain—Etoposide—brain cancer	0.000236	0.00312	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—brain cancer	0.000234	0.0031	CcSEcCtD
Afatinib—Insomnia—Carmustine—brain cancer	0.000233	0.00308	CcSEcCtD
Afatinib—Dyspnoea—Carmustine—brain cancer	0.000229	0.00303	CcSEcCtD
Afatinib—Asthenia—Hydroxyurea—brain cancer	0.000228	0.00302	CcSEcCtD
Afatinib—Insomnia—Temozolomide—brain cancer	0.000225	0.00297	CcSEcCtD
Afatinib—Decreased appetite—Carmustine—brain cancer	0.000224	0.00296	CcSEcCtD
Afatinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000222	0.00294	CcSEcCtD
Afatinib—Dyspnoea—Temozolomide—brain cancer	0.000222	0.00293	CcSEcCtD
Afatinib—Constipation—Carmustine—brain cancer	0.00022	0.00291	CcSEcCtD
Afatinib—Dyspepsia—Temozolomide—brain cancer	0.000219	0.00289	CcSEcCtD
Afatinib—Diarrhoea—Hydroxyurea—brain cancer	0.000218	0.00288	CcSEcCtD
Afatinib—Decreased appetite—Temozolomide—brain cancer	0.000216	0.00286	CcSEcCtD
Afatinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000215	0.00284	CcSEcCtD
Afatinib—Fatigue—Temozolomide—brain cancer	0.000214	0.00283	CcSEcCtD
Afatinib—Cough—Etoposide—brain cancer	0.000213	0.00281	CcSEcCtD
Afatinib—Constipation—Temozolomide—brain cancer	0.000213	0.00281	CcSEcCtD
Afatinib—Dizziness—Hydroxyurea—brain cancer	0.000211	0.00278	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000206	0.00272	CcSEcCtD
Afatinib—ABCG2—cerebellum—brain cancer	0.000204	0.00328	CbGeAlD
Afatinib—Body temperature increased—Carmustine—brain cancer	0.000203	0.00269	CcSEcCtD
Afatinib—Vomiting—Hydroxyurea—brain cancer	0.000202	0.00267	CcSEcCtD
Afatinib—Rash—Hydroxyurea—brain cancer	0.000201	0.00265	CcSEcCtD
Afatinib—Dermatitis—Hydroxyurea—brain cancer	0.000201	0.00265	CcSEcCtD
Afatinib—Headache—Hydroxyurea—brain cancer	0.000199	0.00264	CcSEcCtD
Afatinib—Infection—Etoposide—brain cancer	0.000198	0.00261	CcSEcCtD
Afatinib—Body temperature increased—Temozolomide—brain cancer	0.000197	0.0026	CcSEcCtD
Afatinib—Skin disorder—Etoposide—brain cancer	0.000193	0.00255	CcSEcCtD
Afatinib—Nausea—Hydroxyurea—brain cancer	0.000189	0.0025	CcSEcCtD
Afatinib—Asthenia—Carmustine—brain cancer	0.000185	0.00244	CcSEcCtD
Afatinib—ABCB1—telencephalon—brain cancer	0.000181	0.00291	CbGeAlD
Afatinib—Asthenia—Temozolomide—brain cancer	0.000178	0.00236	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—brain cancer	0.000177	0.00234	CcSEcCtD
Afatinib—Diarrhoea—Carmustine—brain cancer	0.000176	0.00233	CcSEcCtD
Afatinib—Pruritus—Temozolomide—brain cancer	0.000176	0.00233	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—brain cancer	0.000173	0.00229	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000172	0.00227	CcSEcCtD
Afatinib—Fatigue—Etoposide—brain cancer	0.000172	0.00227	CcSEcCtD
Afatinib—Dizziness—Carmustine—brain cancer	0.00017	0.00225	CcSEcCtD
Afatinib—Constipation—Etoposide—brain cancer	0.00017	0.00225	CcSEcCtD
Afatinib—Diarrhoea—Temozolomide—brain cancer	0.00017	0.00225	CcSEcCtD
Afatinib—ABCG2—brain—brain cancer	0.000166	0.00267	CbGeAlD
Afatinib—Dizziness—Temozolomide—brain cancer	0.000164	0.00217	CcSEcCtD
Afatinib—Vomiting—Carmustine—brain cancer	0.000164	0.00216	CcSEcCtD
Afatinib—Rash—Carmustine—brain cancer	0.000162	0.00214	CcSEcCtD
Afatinib—Dermatitis—Carmustine—brain cancer	0.000162	0.00214	CcSEcCtD
Afatinib—Headache—Carmustine—brain cancer	0.000161	0.00213	CcSEcCtD
Afatinib—Vomiting—Temozolomide—brain cancer	0.000158	0.00209	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—brain cancer	0.000157	0.00208	CcSEcCtD
Afatinib—Rash—Temozolomide—brain cancer	0.000157	0.00207	CcSEcCtD
Afatinib—Dermatitis—Temozolomide—brain cancer	0.000157	0.00207	CcSEcCtD
Afatinib—Headache—Temozolomide—brain cancer	0.000156	0.00206	CcSEcCtD
Afatinib—Nausea—Carmustine—brain cancer	0.000153	0.00202	CcSEcCtD
Afatinib—ABCB1—gonad—brain cancer	0.000151	0.00243	CbGeAlD
Afatinib—Nausea—Temozolomide—brain cancer	0.000148	0.00195	CcSEcCtD
Afatinib—ABCB1—pituitary gland—brain cancer	0.000148	0.00237	CbGeAlD
Afatinib—Asthenia—Etoposide—brain cancer	0.000143	0.00189	CcSEcCtD
Afatinib—ABCB1—medulla oblongata—brain cancer	0.000142	0.00229	CbGeAlD
Afatinib—Pruritus—Etoposide—brain cancer	0.000141	0.00186	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—brain cancer	0.000136	0.0018	CcSEcCtD
Afatinib—Dizziness—Etoposide—brain cancer	0.000132	0.00174	CcSEcCtD
Afatinib—ABCB1—midbrain—brain cancer	0.00013	0.00209	CbGeAlD
Afatinib—ABCB1—spinal cord—brain cancer	0.000127	0.00204	CbGeAlD
Afatinib—Vomiting—Etoposide—brain cancer	0.000127	0.00167	CcSEcCtD
Afatinib—Rash—Etoposide—brain cancer	0.000125	0.00166	CcSEcCtD
Afatinib—Dermatitis—Etoposide—brain cancer	0.000125	0.00166	CcSEcCtD
Afatinib—Headache—Etoposide—brain cancer	0.000125	0.00165	CcSEcCtD
Afatinib—Nausea—Etoposide—brain cancer	0.000118	0.00156	CcSEcCtD
Afatinib—ABCB1—endocrine gland—brain cancer	0.000114	0.00184	CbGeAlD
Afatinib—ABCB1—head—brain cancer	0.000113	0.00181	CbGeAlD
Afatinib—ABCB1—central nervous system—brain cancer	0.000103	0.00166	CbGeAlD
Afatinib—ABCB1—cerebellum—brain cancer	0.000101	0.00162	CbGeAlD
Afatinib—ABCB1—brain—brain cancer	8.18e-05	0.00131	CbGeAlD
Afatinib—ERBB2—Disease—APC—brain cancer	1.77e-05	0.000139	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—VEGFA—brain cancer	1.77e-05	0.000139	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—brain cancer	1.74e-05	0.000137	CbGpPWpGaD
Afatinib—ERBB4—Disease—APC—brain cancer	1.74e-05	0.000137	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.74e-05	0.000137	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GLI1—brain cancer	1.74e-05	0.000137	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IRS2—brain cancer	1.74e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—IRS2—brain cancer	1.73e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SUFU—brain cancer	1.71e-05	0.000134	CbGpPWpGaD
Afatinib—ABL1—Immune System—VAV1—brain cancer	1.71e-05	0.000134	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CG—brain cancer	1.7e-05	0.000134	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—brain cancer	1.7e-05	0.000133	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HES1—brain cancer	1.68e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—brain cancer	1.67e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—IRS2—brain cancer	1.67e-05	0.000131	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HES1—brain cancer	1.65e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GFAP—brain cancer	1.65e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—STAT3—brain cancer	1.65e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SUFU—brain cancer	1.65e-05	0.000129	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—RELA—brain cancer	1.65e-05	0.000129	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—ERBB2—brain cancer	1.64e-05	0.000128	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	1.62e-05	0.000127	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—STAT3—brain cancer	1.62e-05	0.000127	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CTNNB1—brain cancer	1.62e-05	0.000127	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—brain cancer	1.61e-05	0.000126	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PDGFRA—brain cancer	1.6e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—VAV1—brain cancer	1.6e-05	0.000125	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GFAP—brain cancer	1.59e-05	0.000125	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—STAT3—brain cancer	1.59e-05	0.000125	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—brain cancer	1.59e-05	0.000125	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PDGFRA—brain cancer	1.57e-05	0.000123	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IRS2—brain cancer	1.57e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HEY1—brain cancer	1.57e-05	0.000123	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SPP1—brain cancer	1.55e-05	0.000122	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—DLL1—brain cancer	1.54e-05	0.00012	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SPP1—brain cancer	1.53e-05	0.00012	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.51e-05	0.000118	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—VEGFA—brain cancer	1.51e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HEY1—brain cancer	1.51e-05	0.000118	CbGpPWpGaD
Afatinib—ERBB2—Immune System—RELA—brain cancer	1.5e-05	0.000117	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DLL1—brain cancer	1.48e-05	0.000116	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH2—brain cancer	1.48e-05	0.000116	CbGpPWpGaD
Afatinib—ERBB4—Immune System—RELA—brain cancer	1.47e-05	0.000116	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ERBB2—brain cancer	1.47e-05	0.000115	CbGpPWpGaD
Afatinib—EGFR—Immune System—VAV1—brain cancer	1.46e-05	0.000114	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO2—brain cancer	1.46e-05	0.000114	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—IL2—brain cancer	1.45e-05	0.000114	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—RELA—brain cancer	1.45e-05	0.000114	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—brain cancer	1.45e-05	0.000113	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ERBB2—brain cancer	1.45e-05	0.000113	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—CTNNB1—brain cancer	1.43e-05	0.000112	CbGpPWpGaD
Afatinib—BLK—Immune System—RELA—brain cancer	1.42e-05	0.000111	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VAV1—brain cancer	1.41e-05	0.000111	CbGpPWpGaD
Afatinib—BLK—Immune System—ERBB2—brain cancer	1.41e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—RELA—brain cancer	1.41e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Immune System—VAV1—brain cancer	1.41e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IRS2—brain cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—ERBB2—brain cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—ABL1—Immune System—PDGFRA—brain cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IRS2—brain cancer	1.38e-05	0.000108	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2C9—brain cancer	1.36e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB4—Disease—ERBB2—brain cancer	1.35e-05	0.000106	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL2—brain cancer	1.35e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Disease—VAV1—brain cancer	1.35e-05	0.000106	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.33e-05	0.000105	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL2—brain cancer	1.33e-05	0.000104	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.32e-05	0.000104	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SHH—brain cancer	1.31e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CTNNB1—brain cancer	1.3e-05	0.000102	CbGpPWpGaD
Afatinib—LCK—Disease—VAV1—brain cancer	1.3e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CTNNB1—brain cancer	1.28e-05	0.000101	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—brain cancer	1.28e-05	0.0001	CbGpPWpGaD
Afatinib—BLK—Immune System—IL2—brain cancer	1.28e-05	0.0001	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CTNNB1—brain cancer	1.26e-05	9.92e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—VEGFA—brain cancer	1.26e-05	9.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TRPC6—brain cancer	1.26e-05	9.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SHH—brain cancer	1.26e-05	9.87e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—STAT3—brain cancer	1.25e-05	9.79e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—RELA—brain cancer	1.24e-05	9.75e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—APC—brain cancer	1.24e-05	9.72e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CG—brain cancer	1.24e-05	9.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTCH1—brain cancer	1.24e-05	9.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMO—brain cancer	1.24e-05	9.71e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—VEGFA—brain cancer	1.24e-05	9.7e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ERBB2—brain cancer	1.23e-05	9.69e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—CTNNB1—brain cancer	1.23e-05	9.67e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IRS2—brain cancer	1.23e-05	9.63e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—CTNNB1—brain cancer	1.22e-05	9.6e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CG—brain cancer	1.22e-05	9.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—APC—brain cancer	1.22e-05	9.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HES1—brain cancer	1.21e-05	9.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TRPC6—brain cancer	1.21e-05	9.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—CTNNB1—brain cancer	1.2e-05	9.43e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IL2—brain cancer	1.2e-05	9.4e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—RELA—brain cancer	1.2e-05	9.39e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PDGFRA—brain cancer	1.19e-05	9.37e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—RELA—brain cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTCH1—brain cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMO—brain cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB2—brain cancer	1.19e-05	9.33e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB2—brain cancer	1.19e-05	9.3e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—CTNNB1—brain cancer	1.18e-05	9.29e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.16e-05	9.12e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BSG—brain cancer	1.16e-05	9.09e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HES1—brain cancer	1.16e-05	9.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PDGFRA—brain cancer	1.16e-05	9.06e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PDGFRA—brain cancer	1.15e-05	9.03e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—RELA—brain cancer	1.15e-05	9.02e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB2—brain cancer	1.14e-05	8.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—STAT3—brain cancer	1.13e-05	8.9e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—brain cancer	1.13e-05	8.9e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SPP1—brain cancer	1.12e-05	8.8e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—brain cancer	1.12e-05	8.77e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HES1—brain cancer	1.12e-05	8.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PDGFRA—brain cancer	1.1e-05	8.65e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—RELA—brain cancer	1.08e-05	8.49e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CTNNB1—brain cancer	1.08e-05	8.47e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—brain cancer	1.08e-05	8.45e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB2—brain cancer	1.08e-05	8.44e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—brain cancer	1.08e-05	8.43e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.07e-05	8.39e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—brain cancer	1.07e-05	8.36e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PDGFRA—brain cancer	1.06e-05	8.34e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IRS2—brain cancer	1.05e-05	8.23e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—brain cancer	1.05e-05	8.22e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.05e-05	8.21e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CTNNB1—brain cancer	1.04e-05	8.17e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—brain cancer	1.03e-05	8.09e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—brain cancer	1.03e-05	8.09e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—brain cancer	1.02e-05	7.99e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—brain cancer	1.02e-05	7.97e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IRS2—brain cancer	1.01e-05	7.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CG—brain cancer	1.01e-05	7.95e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IRS2—brain cancer	1.01e-05	7.93e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—brain cancer	1e-05	7.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—IDH1—brain cancer	9.97e-06	7.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH2—brain cancer	9.89e-06	7.76e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—brain cancer	9.77e-06	7.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—brain cancer	9.75e-06	7.65e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—brain cancer	9.73e-06	7.64e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IRS2—brain cancer	9.68e-06	7.6e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RELA—brain cancer	9.68e-06	7.59e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—brain cancer	9.59e-06	7.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH2—brain cancer	9.53e-06	7.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RELA—brain cancer	9.53e-06	7.48e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—brain cancer	9.52e-06	7.47e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—brain cancer	9.47e-06	7.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VAV1—brain cancer	9.43e-06	7.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTNNB1—brain cancer	9.41e-06	7.38e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—brain cancer	9.38e-06	7.36e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—brain cancer	9.34e-06	7.33e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IRS2—brain cancer	9.33e-06	7.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VAV1—brain cancer	9.09e-06	7.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CG—brain cancer	8.96e-06	7.03e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APC—brain cancer	8.96e-06	7.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	8.78e-06	6.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—brain cancer	8.72e-06	6.84e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—brain cancer	8.59e-06	6.74e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—APC—brain cancer	8.55e-06	6.71e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—brain cancer	8.5e-06	6.67e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—RELA—brain cancer	8.47e-06	6.64e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—brain cancer	8.42e-06	6.6e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CTNNB1—brain cancer	8.42e-06	6.6e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—brain cancer	8.37e-06	6.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CTNNB1—brain cancer	8.29e-06	6.5e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—brain cancer	8.25e-06	6.47e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APC—brain cancer	8.24e-06	6.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—brain cancer	8.2e-06	6.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HES1—brain cancer	8.11e-06	6.36e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—brain cancer	7.92e-06	6.21e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—brain cancer	7.88e-06	6.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HES1—brain cancer	7.82e-06	6.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFRA—brain cancer	7.72e-06	6.06e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—brain cancer	7.69e-06	6.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—brain cancer	7.63e-06	5.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—brain cancer	7.5e-06	5.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—brain cancer	7.46e-06	5.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFRA—brain cancer	7.44e-06	5.84e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—brain cancer	7.41e-06	5.81e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—brain cancer	7.36e-06	5.78e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—brain cancer	7.34e-06	5.75e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—brain cancer	7.3e-06	5.72e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RELA—brain cancer	7.24e-06	5.68e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—brain cancer	7.23e-06	5.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—brain cancer	7.23e-06	5.67e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—brain cancer	7.19e-06	5.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—brain cancer	7.13e-06	5.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RELA—brain cancer	7e-06	5.49e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RELA—brain cancer	6.97e-06	5.47e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—brain cancer	6.95e-06	5.46e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—brain cancer	6.93e-06	5.44e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—brain cancer	6.82e-06	5.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS2—brain cancer	6.78e-06	5.32e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—brain cancer	6.71e-06	5.27e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—brain cancer	6.69e-06	5.25e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—brain cancer	6.67e-06	5.23e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—brain cancer	6.64e-06	5.21e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—brain cancer	6.57e-06	5.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS2—brain cancer	6.53e-06	5.13e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—brain cancer	6.52e-06	5.11e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—brain cancer	6.42e-06	5.04e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—brain cancer	6.4e-06	5.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—brain cancer	6.3e-06	4.94e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—brain cancer	6.29e-06	4.94e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—brain cancer	6.28e-06	4.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—brain cancer	6.14e-06	4.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—brain cancer	6.08e-06	4.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—brain cancer	6.06e-06	4.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—brain cancer	5.99e-06	4.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—brain cancer	5.99e-06	4.7e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—brain cancer	5.83e-06	4.58e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—brain cancer	5.81e-06	4.56e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—brain cancer	5.77e-06	4.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—brain cancer	5.77e-06	4.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—brain cancer	5.6e-06	4.39e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—brain cancer	5.6e-06	4.39e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—brain cancer	5.51e-06	4.33e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—brain cancer	5.48e-06	4.3e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—brain cancer	5.36e-06	4.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—brain cancer	5.3e-06	4.16e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—brain cancer	5.29e-06	4.15e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—brain cancer	5.06e-06	3.97e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—brain cancer	4.93e-06	3.87e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—brain cancer	4.88e-06	3.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—brain cancer	4.82e-06	3.78e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—brain cancer	4.8e-06	3.77e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—brain cancer	4.71e-06	3.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RELA—brain cancer	4.68e-06	3.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—brain cancer	4.65e-06	3.65e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—brain cancer	4.53e-06	3.56e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RELA—brain cancer	4.51e-06	3.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—brain cancer	4.48e-06	3.52e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—brain cancer	4.44e-06	3.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—brain cancer	4.21e-06	3.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—brain cancer	4.11e-06	3.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—brain cancer	4.07e-06	3.19e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—brain cancer	4.06e-06	3.19e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—brain cancer	4.05e-06	3.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—brain cancer	3.96e-06	3.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—brain cancer	3.92e-06	3.08e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—brain cancer	3.61e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—brain cancer	3.58e-06	2.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—brain cancer	3.55e-06	2.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—brain cancer	3.45e-06	2.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—brain cancer	3.42e-06	2.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—brain cancer	3.3e-06	2.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—brain cancer	3.18e-06	2.49e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—brain cancer	3.11e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—brain cancer	2.71e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—brain cancer	2.61e-06	2.05e-05	CbGpPWpGaD
